Performance Comparison of Microfluidic and Immunomagnetic Platforms for Pancreatic CTC Enrichment
November 15, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Corvert
Synonyms :
ibutilide
Class :
Antidysrhythmic, III
Brand Name :
Corvert
Synonyms :
ibutilide
Class :
Antidysrhythmic, III
Dosage Forms & StrengthsÂ
Injectable solutionÂ
0.1mg/mlÂ
>60 kg: 1 mg (one vial) intravenous infusion. May repeat after ten minutes when necessary
<60 kg: 0.01 mg/kg (0.1 mL/kg) intravenous infusion. May repeat after ten minutes when necessary
Safety and Efficacy not establishedÂ
Refer adult dosingÂ
may increase the QTc prolonging effect of QT-prolonging Class III Antiarrhythmics
may increase the QTc prolonging effect of QT-prolonging Class III Antiarrhythmics
may increase the QTc prolonging effect of QT-prolonging Class III Antiarrhythmics
may increase the QTc prolonging effect of QT-prolonging Class III Antiarrhythmics
may increase the QTc prolonging effect of QT-prolonging Class III Antiarrhythmics
may increase the QTc prolonging effect of QT-prolonging Class III Antiarrhythmics
may increase the QTc prolonging effect of QT-prolonging Class III Antiarrhythmics
may increase the QTc prolonging effect of QT-prolonging Class III Antiarrhythmics
may increase the QTc prolonging effect of QT-prolonging Class III Antiarrhythmics
may increase the QTc prolonging effect of QT-prolonging Class III Antiarrhythmics
may increase the QTc prolonging effect of QT-prolonging Class III Antiarrhythmics
may increase the QTc prolonging effect of QT-prolonging Class III Antiarrhythmics
may increase the QTc prolonging effect of QT-prolonging agents
may increase the QTc prolonging effect of QT-prolonging agents
may increase the QTc prolonging effect of QT-prolonging agents
may increase the QTc prolonging effect of QT-prolonging agents
may increase the QTc prolonging effect of QT-prolonging agents
may increase the QTc prolonging effect of QT-prolonging agents
may increase the QTc prolonging effect of QT-prolonging agents
may increase the QTc prolonging effect of QT-prolonging agents
may increase the QTc prolonging effect of QT-prolonging agents
may increase the QTc prolonging effect of QT-prolonging agents
may increase the QTc prolonging effect of QT-prolonging agents
may increase the QTc prolonging effect of QT-prolonging agents
may increase the QTc prolonging effect of QT-prolonging agents
may increase the QTc prolonging effect of QT-prolonging agents
may increase the QTc prolonging effect of QT-prolonging agents
may increase the QTc prolonging effect of QT-prolonging Class III Antiarrhythmics
may increase the QTc prolonging effect of QT-prolonging Class III Antiarrhythmics
may increase the QTc prolonging effect of QT-prolonging Class III Antiarrhythmics
may increase the QTc prolonging effect of QT-prolonging Class III Antiarrhythmics
may increase the QTc prolonging effect of QT-prolonging Class III Antiarrhythmics
may increase the QTc prolonging effect of QT-prolonging agents
It may enhance QTc interval when combined with erythromycin stearate
It may enhance QTc interval when combined with perphenazine
It may enhance QTc interval when combined with epinephrine
when both drugs are combined, there may be an increase in qtc interval  
may increase the QTc prolonging effect of QT-prolonging agents
when both drugs are combined, there may be an increased risk or severity of QTC prolongation  
QTc interval is increased both by lenvatinib and ibutilide
both lapatinib and ibutilide increase the QTc interval
ibutilide and gilteritinib, when used in combination, increase the QTc interval
may increase the QTc prolonging effect of QT-prolonging agents
may increase the QTc prolonging effect of QT-prolonging agents
may increase the QTc prolonging effect of QT-prolonging agents
may increase the QTc prolonging effect of QT-prolonging agents
may increase the QTc prolonging effect of QT-prolonging agents
may increase the QTc prolonging effect of QT-prolonging agents
may increase the QTc prolonging effect of QT-prolonging agents
may increase the QTc prolonging effect of QT-prolonging agents
may increase the QTc prolonging effect of QT-prolonging agents
may increase the QTc prolonging effect of QT-prolonging agents
may increase the QTc prolonging effect of QT-prolonging agents
ibutilide leads to a reduction in the rate of excretion of nitric oxide, which leads to an increased level of serum
Actions and Spectrum:Â
Frequency definedÂ
1-10%Â
Bradycardia (2%)Â
Hypotension (2%)Â
QTc interval prolongation (<2%)Â
Headache (4%)Â
HTN (2%)Â
Palpitations (2%)Â
Nausea (>2%)Â Â
<1%Â
Erythematous bullous lesionsÂ
Renal failureÂ
Ventricular tachycardiaÂ
Heart blockÂ
Heart failureÂ
Nodal arrhythmiaÂ
SyncopeÂ
Torsades de pointesÂ
Contraindications/caution:Â
Contraindications:Â
Caution:Â
Pregnancy consideration: Insufficient data availableÂ
Lactation:Â Â
Pregnancy category:Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.  Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this categoryÂ
Pharmacology:Â
ibutilide works by blocking potassium channels in the heart, which prolongs the action potential duration and refractory period in the atrial and ventricular myocardium. This results in an antiarrhythmic effect by helping to prevent the reentry of abnormal electrical signals in the heartÂ
Pharmacodynamics:Â
ibutilide has a relatively narrow therapeutic index, meaning that the therapeutic dose is close to the toxic dose. The drug can cause prolongation of the QT interval on the electrocardiogram, which can lead to a potentially life-threatening arrhythmia called torsades de pointes. Therefore, patients receiving ibutilide should be closely monitored for changes in their QT interval and other potential adverse effects.Â
Pharmacokinetics:Â
AbsorptionÂ
ibutilide is administered intravenously and is rapidly and completely absorbed following injection. Â
DistributionÂ
The volume of distribution of ibutilide is approximately 7 L/kg, suggesting that the drug is widely distributed throughout the body. The plasma protein binding of ibutilide is about 40-50%. Â
MetabolismÂ
ibutilide is metabolized by the liver through the cytochrome P450 enzyme system, predominantly by the CYP3A4 isoform, into inactive metabolites. Â
Elimination and ExcretionÂ
The elimination half-life of ibutilide is approximately 6 hours. The drug is excreted primarily in the urine, with approximately 50-60% of the dose being excreted unchanged in the urine. The remaining portion of the drug is excreted in feces.Â
Administration:Â
ibutilide is administered intravenously (IV) in a hospital or clinical setting. It is typically given as a single dose over 10 minutes. The recommended dose of ibutilide is based on the patient’s body weight and cardiac function and is usually between 0.01 and 0.025 mg/kgÂ
Patient information leafletÂ
Generic Name: ibutilideÂ
Pronunciation: [ eye-BUE-til-ide ]Â
Why do we use ibutilide?Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
